| Literature DB >> 25310005 |
Stefan Markun1, Barbara M Holzer2, Roksana Rodak3, Vladimir Kaplan2, Claudia C Wagner3, Edouard Battegay4, Lukas Zimmerli2.
Abstract
BACKGROUND: Patients with multimorbidity are an increasing concern in healthcare. Clinical practice guidelines, however, do not take into account potential therapeutic conflicts caused by co-occurring medical conditions. This makes therapeutic decisions complex, especially in emergency situations.Entities:
Mesh:
Year: 2014 PMID: 25310005 PMCID: PMC4195608 DOI: 10.1371/journal.pone.0110309
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics of therapeutic conflicts in 166 emergency patients with multimorbity.
| Variable | Number of patients | Percentage of study population |
| Gender | ||
| Female | 68 | 41.0% |
| Male | 98 | 59.0% |
| Age (years) | ||
| <40 | 24 | 14.5% |
| 40 to 59 | 34 | 20.5% |
| 60 to 79 | 76 | 45.8% |
| >80 | 32 | 19.3% |
| Mode of admission: | ||
| Physician | 62 | 37.3% |
| Self-referred | 53 | 31.9% |
| Ambulance | 46 | 27.7% |
| Others | 5 | 3.0% |
| Number of active diagnoses per patient: | ||
| 2–4 | 53 | 31.9% |
| 5–7 | 46 | 27.7% |
| 8–10 | 44 | 26.5% |
| ≥11 | 23 | 13.9% |
| Duration of hospitalization (days): | ||
| 1–3 days | 47 | 28.3% |
| 4–7 days | 39 | 23.5% |
| 8–14 days | 40 | 24.1% |
| ≥14 days | 40 | 24.1% |
| Patients without therapeutic conflicts | 84 | 50.6% |
| Patients with therapeutic conflicts: | 82 | 49.4% |
| Patients with major conflicts only | 14 | 8.4% |
| Patients with minor conflicts only | 34 | 20.5% |
| Patients with both major and minor conflicts | 34 | 20.5% |
Figure 1Prevalence of the most frequently diagnosed medical conditions of 166 emergency patients with multimorbity*.
*Only those medical conditions diagnosed in ≥4% of the study population are shown PAD = peripheral artery disease; COPD = chronic obstructive pulmonary disease.
Major therapeutic conflicts identified in 166 emergency patients with multimorbity*.
| Type of therapy recommended by CPG | Medical conflict | Number of conflicts | Percentage of study population |
| Chemotherapy | 22 | ||
| Infection | 8 | 4.8% | |
| Aplasia; neutropenia | 4 | 2.4% | |
| Thrombocytes <50 G/L | 4 | 2.4% | |
| Gastroenteritis | 3 | 1.8% | |
| Gastrointestinal bleeding | 1 | 0.6% | |
| Renal failure | 1 | 0.6% | |
| Hemoglobin <6 g/dL | 1 | 0.6% | |
| Immunosuppression | 21 | ||
| Infection | 18 | 10.8% | |
| Aplasia; neutropenia | 3 | 1.8% | |
| Acetylsalicylic acid | 9 | ||
| Gastrointestinal bleeding | 4 | 2.4% | |
| Acetylsalicylic acid allergy | 3 | 1.8% | |
| Subdural hemorrhage | 1 | 0.6% | |
| INR >6 | 1 | 0.6% | |
| Contrast agent | 3 | ||
| Renal failure | 2 | 1.2% | |
| Contrast dye allergy | 1 | 0.6% | |
| Heparin | 2 | ||
| Gastrointestinal bleeding | 1 | 0.6% | |
| Thrombocytes <50 G/L | 1 | 0.6% | |
| Antihypertensive agents | 2 | ||
| Orthostatic dysregulation | 2 | 1.2% | |
| Fluid replacement | 2 | ||
| Acute congestive heart failure | 2 | 1.2% | |
| Estrogen replacement | 2 | ||
| Acute coronary syndrome | 2 | 1.2% | |
| Oral anticoagulant | 1 | ||
| Gastrointestinal bleeding | 1 | 0.6% | |
| Pleurocentesis | 1 | ||
| Thrombocytes <50 G/L | 1 | 0.6% | |
| Ganciclovir | 1 | ||
| Aplasia; neutropenia | 1 | 0.6% |
CPG = Clinical practice guideline.
INR = international normalized ratio index of blood coagulability.
*Major therapeutic conflict was defined as a situation where clinical practice guidelines recommend a treatment of one medical condition that is absolutely contraindicated because of a co-existing condition.
Neutropenia defined as neutrophilic granulocytes <1.40 G/L.
Renal failure defined as an estimated GFR [glomerular filtration rate] <60 mL/min from MDRD [Modification of Diet in Renal Disease Study Group] equation.
Minor therapeutic conflicts identified in 166 emergency patients with multimorbity*.
| Type of therapy recommended by CPG | Medical conflict | Number of conflicts | Percentage of study population |
| Steroid | 53 | ||
| Arterial hypertension | 16 | 9.6% | |
| Diabetes mellitus | 13 | 7.8% | |
| Osteoporosis | 9 | 5.4% | |
| Affective disorder | 5 | 3.0% | |
| Sleeping disorder | 5 | 3.0% | |
| Obesity | 3 | 1.8% | |
| Acute congestive heart failure | 2 | 1.2% | |
| Diuretic | 28 | ||
| Renal failure | 23 | 13.9% | |
| Infection | 3 | 1.8% | |
| Hyperparathyroidism | 2 | 1.2% | |
| Antihypertensive agents | 26 | ||
| PAD | 15 | 9.0% | |
| Gastrointestinal bleeding | 8 | 4.8% | |
| Sepsis | 3 | 1.8% | |
| Immunosuppression | 19 | ||
| Renal failure | 15 | 9.0% | |
| Gastroenteritis | 2 | 1.2% | |
| Carrier of multiresistant bacteria | 1 | 0.6% | |
| Thrombocytes <50 G/L | 1 | 0.6% | |
| Beta-blocker | 12 | ||
| PAD | 4 | 2.4% | |
| Acute congestive heart failure | 4 | 2.4% | |
| Heart block (first-degree) | 2 | 1.2% | |
| Asthma | 2 | 1.2% | |
| Chemotherapy | 10 | ||
| Renal failure | 7 | 4.2% | |
| Esophagitis or GERD | 2 | 1.2% | |
| Skin lesion | 1 | 0.6% | |
| Aspirin | 9 | ||
| Esophagitis or GERD | 8 | 4.8% | |
| Peptic ulcer | 1 | 0.6% | |
| Opioid | 5 | ||
| COPD | 2 | 1.2% | |
| Prostate hyperplasia | 2 | 1.2% | |
| Constipation | 1 | 0.6% | |
| Compression stockings | 2 | ||
| PAD | 2 | 1.2% | |
| Fluid replacement | 2 | ||
| Mitral insufficiency | 2 | 1.2% | |
| Estrogen replacement | 2 | ||
| Arterial hypertension | 2 | 1.2% | |
| Oxygen | 2 | ||
| COPD | 2 | 1.2% | |
| Benzodiazepine | 1 | ||
| Encephalopathy | 1 | 0.6% | |
| NSAID | 1 | ||
| Esophagitis or GERD | 1 | 0.6% | |
| ACE inhibitor | 1 | ||
| Hyperpotassemia | 1 | 0.6% |
CPG = Clinical practice guideline.
PAD = peripheral artery disease; GERD = gastroesophageal reflux disease; COPD = chronic obstructive pulmonary disease; ACE = angiotensin-converting enzyme; NSAID = nonsteroidal anti-inflammatory drug.
*Minor therapeutic conflict was defined as a where clinical practice guidelines recommend a treatment of one medical condition that is relatively contraindicated because of a co-existing condition, but where the treatment is possible without adverse effects if certain precautions are taken.
Renal failure defined as an estimated GFR [glomerular filtration rate] <60 mL/min from MDRD [Modification of Diet in Renal Disease Study Group] equation.
Figure 2Number of patients with recommended therapies and the associated therapeutic conflicts identified in 166 emergency patients with multimorbity*.
ACE = angiotensin-converting enzyme; NSAID = nonsteroidal anti-inflammatory drug *Major therapeutic conflict was defined as a situation where clinical practice guidelines recommend a treatment of one medical condition that is absolutely contraindicated because of a co-existing condition. Minor therapeutic conflict was defined as a where clinical practice guidelines recommend a treatment of one medical condition that is relatively contraindicated because of a co-existing condition, but where the treatment is possible without adverse effects if certain precautions are taken.
Figure 3Mean number of therapeutic conflicts with respect to the number of concurrent medical conditions per patient in 166 emergency patients with multimorbity.
CI = confidence interval.